EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE tablet, film coated

País: Estados Unidos

Língua: inglês

Origem: NLM (National Library of Medicine)

Ingredientes ativos:

EMTRICITABINE (UNII: G70B4ETF4S) (EMTRICITABINE - UNII:G70B4ETF4S), TENOFOVIR DISOPROXIL FUMARATE (UNII: OTT9J7900I) (TENOFOVIR ANHYDROUS - UNII:W4HFE001U5)

Disponível em:

Pharmasource Meds, LLC

Via de administração:

ORAL

Tipo de prescrição:

PRESCRIPTION DRUG

Indicações terapêuticas:

Emtricitabine and tenofovir disoproxil fumarate tablets are indicated in combination with other antiretroviral agents for the treatment of HIV-1 infection in adults and pediatric patients weighing at least 17 kg [see Clinical Studies ( 14)].  Emtricitabine and tenofovir disoproxil fumarate tablets are indicated in at-risk adults and adolescents weighing at least 35 kg for pre-exposure prophylaxis (PrEP) to reduce the risk of sexually acquired HIV-1 infection. Individuals must have a negative HIV-1 test immediately prior to initiating emtricitabine and tenofovir disoproxil fumarate tablets for HIV-1 PrEP [see Dosage and Administration ( 2.2), Warnings and Precautions ( 5.2)]. Emtricitabine and tenofovir disoproxil fumarate tablets for HIV-1 PrEP is contraindicated in individuals with unknown or positive HIV-1 status [ see Warnings and Precautions ( 5.2)]. Pregnancy Exposure Registry There is a

Resumo do produto:

Emtricitabine and tenofovir disoproxil fumarate tablets are available as follows: 200 mg of emtricitabine and 300 mg of tenofovir disoproxil fumarate (equivalent to 245 mg of tenofovir disoproxil) are white, capsule shaped, film-coated tablets debossed with "L-24" on one side and plain on the other surface. Bottle of 3 NDC 82982-056-03 Store below 30°C (86° F). • Keep container tightly closed

Status de autorização:

Abbreviated New Drug Application

Folheto informativo - Bula

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE- EMTRICITABINE AND
TENOFOVIR
DISOPROXIL FUMARATE TABLET, FILM COATED
Pharmasource Meds, LLC
----------
MEDICATION GUIDE
Emtricitabine and Tenofovir Disoproxil Fumarate Tablets
(EM-trye-SYE-ta-been and ten-OF-oh-vir DYE-soe-PROX-il FUEma-rate)
Read this Medication Guide before you start taking emtricitabine and
tenofovir disoproxil fumarate
tablets and each time you get a refill. There may be new information.
This information does not take the
place of talking to your healthcare provider about your medical
condition or your treatment.
This Medication Guide provides information about two different ways
that emtricitabine and tenofovir
disoproxil fumarate tablets may be used. See the section
“ What is emtricitabine and tenofovir disoproxil fumarate
tablets?” for detailed information about how
emtricitabine and tenofovir disoproxil fumarate tablets may be used.
What is the most important information I should know about
emtricitabine and tenofovir disoproxil
fumarate tablets?
Emtricitabine and tenofovir disoproxil fumarate tablets can cause
serious side effects, including:
• Worsening of hepatitis B virus infection (HBV). Your healthcare
provider will test you for HBV before
start or when you start treatment with emtricitabine and tenofovir
disoproxil fumarate tablets. If you have
HBV infection and take emtricitabine and tenofovir disoproxil fumarate
tablets, your HBV may get worse
(flare-up) if you stop taking emtricitabine and tenofovir disoproxil
fumarate tablets. A “flare-up” is when
your HBV infection suddenly returns in a worse way than before.
Do not run out of emtricitabine and tenofovir disoproxil fumarate
tablets. Refill your prescription or talk
to your healthcare provider before your emtricitabine and tenofovir
disoproxil fumarate tablets is all gone.
Do not stop taking emtricitabine and tenofovir disoproxil fumarate
tablets without first talking to your
healthcare provider.
If you stop taking emtricitabine and tenofovir disoproxil fumarate
tablets,

Características técnicas

EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE- EMTRICITABINE AND
TENOFOVIR DISOPROXIL FUMARATE TABLET, FILM COATED
PHARMASOURCE MEDS, LLC
----------
HIGHLIGHTS OF PRESCRIBING INFORMATION
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS. THESE
HIGHLIGHTS DO NOT
INCLUDE ALL THE INFORMATION NEEDED TO USE EMTRICITABINE AND TENOFOVIR
DISOPROXIL
FUMARATE TABLETS SAFELY AND EFFECTIVELY. SEE FULL PRESCRIBING
INFORMATION FOR
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS.
EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS, FOR ORAL USE
INITIAL U.S. APPROVAL: 2004
WARNING: POSTTREATMENT ACUTE EXACERBATION OF HEPATITIS B AND RISK OF
DRUG
RESISTANCE WITH USE OF EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE
TABLETS FOR HIV-1 PRE-EXPOSURE PROPHYLAXIS (PREP) IN UNDIAGNOSED EARLY
HIV-1
INFECTION SEE FULL PRESCRIBING INFORMATION FOR COMPLETE BOXED WARNING.
• SEVERE ACUTE EXACERBATIONS OF HEPATITIS B (HBV) HAVE BEEN REPORTED
IN HBV-INFECTED
INDIVIDUALS WHO HAVE DISCONTINUED EMTRICITABINE AND TENOFOVIR
DISOPROXIL FUMARATE
TABLETS. HEPATIC FUNCTION SHOULD BE MONITORED CLOSELY IN THESE
INDIVIDUALS WHO
DISCONTINUE EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS.
IF APPROPRIATE
ANTI-HEPATITIS B THERAPY MAY BE WARRANTED. (5.1)
• EMTRICITABINE AND TENOFOVIR DISOPROXIL FUMARATE TABLETS USED FOR
HIV-1 PREP MUST
ONLY BE PRESCRIBED TO INDIVIDUALS CONFIRMED TO BE HIV-NEGATIVE
IMMEDIATELY PRIOR TO
INITIATING AND AT LEAST EVERY 3 MONTHS DURING USE. DRUG-RESISTANT
HIV-1 VARIANTS HAVE
BEEN IDENTIFIED WITH THE USE OF EMTRICITABINE AND TENOFOVIR DISOPROXIL
FUMARATE TABLETS
FOR HIV-1 PREP FOLLOWING UNDETECTED ACUTE HIV-1 INFECTION. DO NOT
INITIATE EMTRICITABINE
AND TENOFOVIR DISOPROXIL FUMARATE TABLETS FOR HIV-1 PREP IF SIGNS OR
SYMPTOMS OF ACUTE
HIV INFECTION ARE PRESENT UNLESS NEGATIVE INFECTION STATUS IS
CONFIRMED. ( 5.2)
RECENT MAJOR CHANGES
Indications and Usage
HIV-1 Pre-Exposure Prophylaxis (PrEP) ( 1.2)
06/2020
Dosage and Administration
HIV-1 Screening for Individuals Receiving Emtricitabine and Tenofovir